Ground breaking Technology Transfer Agreement Between BGI Europe And NIM Genetics Creates Spain’s First Domestically Processed Non-Invasive Prenatal Test--- 8 Dec 2014
December 3rd, 2014 – BGI Europe and NIM Genetics, one of Spain’s leading genetic diagnostics companies, are pleased to announce the signing of an exclusive technology transfer agreement whereby BGI Europe will transfer its science and technology in the field of non-invasive prenatal testing.
This will enable NIM Genetics to start in-country sequencing services as part of the provision of its market leading non-invasive prenatal test, TrisoNIM® Advance, thereby significantly reducing result turnaround times for patients.
TrisoNIM® Advance is a highly accurate non-invasive prenatal test that detects the risk of certain genetic conditions, such as Down syndrome, from as early as week 10 of pregnancy. The test poses zero risk to the mother or fetus and reduces the rate of unnecessary amniocenteses performed on women, thereby exposing fewer women to the risk of miscarriage associated with this procedure.
TrisoNIM® Advance is marketed as the NIFTY® test in other European markets. For more information regarding the test, please see niftytest.com.
Media Contact (Europe)
Name: Matthew Poulter
Tel: +45 30724544